See the DrugPatentWatch profile for Ingrezza
What was Ingrezza’s market share in TD 2025?
The information you provided doesn’t include any market-share data for Ingrezza for TD 2025, so I can’t give an accurate figure.
Do you mean “TD 2025” as a specific country, tender, or time period?
“TD 2025” can refer to different things depending on the source (for example: a territory/country code, a trade designation, or a particular reporting window). If you tell me what “TD 2025” stands for and which geography or dataset you’re using, I can align the answer to that exact definition.
Where can market-share numbers for Ingrezza be found?
Market-share numbers are often published through:
- pharmacy/claims analytics firms (e.g., IQVIA-style reports),
- national regulator/HTA sources by country,
- company financial disclosures (sometimes by product, sometimes not by market share),
- payor or tender market reports.
If you share the link or name of the dataset/report you mean by “TD 2025,” I can extract and summarize the Ingrezza market share from it.
Can you confirm which product you mean?
“Ingrezza” is valbenazine. If you meant a different product (or a different way of defining the market, such as “VMAT2 inhibitors” vs “tardive dyskinesia drugs”), that will change the market-share calculation.
Reply with:
1) what “TD 2025” refers to (and the country/region), and
2) where you’re seeing the definition (report link or title),
and I’ll produce the exact Ingrezza market share for that period.